Compare iShares Self-Driving EV and Tech (IDRV) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Self-Driving EV and Tech trades at $32 (market cap $258.76M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 3.8× iShares Self-Driving EV and Tech's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 75 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IDRV | MRVI | |
|---|---|---|
Market Cap | $258.76M | $972.90M |
Volume | 39,075 | 4,325,710 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $9.00 |
52-Week Low | $32.18 | $2.83 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $32.78, up 0.43% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from lukewarm US electric vehicle adoption despite global EV sales growth. Key support sits at $32 with resistance at $33-34 levels, while oscillators remain neutral suggesting potential consolidation.
The EV sector faces mixed signals with regulatory uncertainty and oil price volatility creating near-term challenges. Long-term prospects remain tied to global EV adoption trends, particularly in China and Europe where growth continues. Investors should weigh regulatory risks against the sector's structural growth trajectory.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
